Regenerative Medical Technology Group Inc
regenmedtechgroup.comWhat Do They Do?
Provides regenerative medicine training, biologic products and medical equipment to physicians and clinics, and treatments to patients.
10-K for FY2025, filed May 14, 2026We support physicians, medical providers, and affiliated clinics with the latest protocols, biologics, automated processing systems…View ↗
Cellgenic advanced significantly with a fully operational, scalable manufacturing infrastructure supporting advanced exosome production…View ↗
Our Cellular Institute and affiliated clinics evolved into five-star regenerative medicine centers, emphasizing exceptional patient…View ↗
How Do They Make Money?
Physicians and clinics buy training, products and equipment, with training counted when seminars end and products and equipment when shipped or picked up. Patient-procedure revenue comes as services are performed.
10-K for FY2025, filed May 14, 2026The Company offers stem cell and exosome certification training programs for physicians and healthcare professionals. The performance…View ↗
The Company sells regenerative medicine and related products directly to physicians and clinics. Products are generally sold at the point…View ↗
The Company sells medical and regenerative medicine equipment to physicians and clinics. Equipment is shipped either directly from the…View ↗
The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product to a customer or as…View ↗
-
10-K for FY2025, filed May 14, 2026
FY2025 revenue by product or service ↗
$5.1M
-
10-K for FY2025, filed May 14, 2026
$5.1M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Training
Sold outright
10-K for FY2025, filed May 14, 2026 |
22%
FY2022: 18%
|
Training, FY2025
$1.1M Sources
|
Sold outright |
|
Product supplies
Sold outright
10-K for FY2025, filed May 14, 2026 |
40%
FY2022: 57%
|
Product supplies, FY2025
$2M Sources
|
Sold outright |
|
Equipment
Sold outright
|
1.5%
FY2022: 11%
|
Equipment, FY2025
$75.8K Sources
|
Sold outright |
|
Patient procedures
Sold outright
10-K for FY2025, filed May 14, 2026 |
37%
FY2022: 14%
|
Patient procedures, FY2025
$1.9M Sources
|
Sold outright |
Who Are Their Customers?
Physicians and clinics buy products directly and take training; patients receive treatments through the company's clinics and affiliated network.
10-K for FY2025, filed May 14, 2026The Company offers stem cell and exosome certification training programs for physicians and healthcare professionals. The performance…View ↗
The Company sells regenerative medicine and related products directly to physicians and clinics. Products are generally sold at the point…View ↗
Our Cellular Institute and affiliated clinics evolved into five-star regenerative medicine centers, emphasizing exceptional patient…View ↗
Complementing the Institute, the Stem Cell Center operates as our primary patient-facing clinical brand and service platform. It functions…View ↗
Do Revenues Turn Into Profits?
No. It lost $7.8M in FY2025.
10-K for FY2025, filed May 14, 2026
−$867.2KView ↗
10-K for FY2025, filed May 14, 2026
−$7.8MView ↗
10-K for FY2025, filed May 14, 2026
−$1.3MView ↗
How Are They Changing?
Growing. Revenue grew 11.6x in 4 years, from $437.9K in FY2021 to $5.1M in FY2025, about 85% a year.
In-house manufacturing
The earlier report described a move from reselling to in-house Cellgenic products; the latest describes operating manufacturing infrastructure for exosomes, stem cells, and peptides.
10-K for FY2022, filed Apr 14, 2023 10-K for FY2025, filed May 14, 2026Solidifying and increasing our Presence worldwide www.cellgenic.com, we are completing our new catalog of Cell Therapy products…View ↗
Cellgenic advanced significantly with a fully operational, scalable manufacturing infrastructure supporting advanced exosome production…View ↗
Loading...
